neurosoft-bio.comCrawled Nov 11, 2026
Neurosoft Bioelectronics develops Brain Computer Interface (BCI) solutions, including SOFT ECoG, MINDZ, SOFT TINNIT, and Synapsuit for mobility support.
Neurosoft Bioelectronics has published over 20 peer-reviewed articles and holds 25+ patents in soft brain interfaces and neuroprosthetics.
Tinnitus is a debilitating condition affecting millions worldwide, severely impacting their quality of life. For those with severe tinnitus, the constant ringing in the ears is not just an annoyance; it's a significant health burden with no effective cure available today.
Neurosoft Bioelectronics operates a medical-grade production line at Campus Biotech, Switzerland, meeting ISO and GMP standards for neurotechnology.
listen to the podcast
Geneva, Switzerland and Xiamen, Fujian — October 16th, 2026 — Neurosoft Bioelectronics, a developer of high-bandwidth brain-computer interfaces (BCIs), today announced that it has won a gold prize in the 2026 Fujian Global Innovation and Entrepreneurship Competition in the Biotechnology track.
Neurosoft Bioelectronics introduces its team, including co-founders and experts in research, manufacturing, and clinical affairs.
Neurosoft Bioelectronics offers brain interface innovations, media coverage in publications like *Forbes* and *Scientific American*, and career opportunities.
Neurosoft Bioelectronics advances Brain-Computer Interfaces (BCI) with ultra-soft, minimally invasive technology, reducing risks and improving treatment outcomes.
Neurosoft Bioelectronics advances Brain-Computer Interfaces (BCI) with ultra-soft, minimally invasive technology, reducing risks and improving treatment outcomes.
This website is published by Neurosoft Bioelectronics SA, a public limited company registered in the Geneva Commercial Register under number CHE-325.358.554. Address: Campus Biotech, Chemin des Mines 9, 1202 Geneva, Switzerland Email: contact@neurosoft-bio.com